Page 36 - Confidence Interval News Today

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved...

HORSHAM, PA - The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration has approved IMBRUVICA for the treatment of pediatric patients one... | August 25, 2022

Teclistamab, an off-the-shelf (ready to use) subcutaneously administered therapy, induced deep and rapid responses in triple-class exposed patients with relapsed and refractory multiple myeloma1 The

The U.S. Food and Drug Administration approved the use of IMBRUVICA for the treatment of pediatric patients one year and older with cGVHD after failure of one...

1. This national cohort study from Singapore showed a significant reduction in SARS-CoV-2 omicron variant infections in children vaccinated with BNT162b2 as compared to unvaccinated children. 2. Vaccination with BNT162b2 in children is also associated with reduced hospitalization due to SARS-CoV-2 omicron variant infection. Evidence Rating Level: 1 (Excellent) Study Rundown: The omicron variant of

1. Cinpanemab did not show clinical efficacy in preventing early Parkinson’s disease (PD) progression compared to placebo. 2. There was no difference in imaging results of dopamine transporters between cinpanemab and placebo groups. Evidence Rating Level: 1 (Excellent) Study Rundown: PD is the second most prevalent neurodegenerative disease worldwide. The mainstay of treatment is dopamine

1. Prasinezumab had no meaningful effect on global or imaging measures of Parkinson’s disease progression. 2. Prasinezumab therapy was associated with increased infusion reactions compared to placebo. Evidence Rating Level: 1 (Excellent) Study Rundown: Aggregated a-synuclein is a main factor in the pathogenesis of Parkinson’s disease. Prasinezumab was designed as a monoclonal antibody to bind

1. Rare mutations in CIDEB are associated with a decreased risk of developing liver cirrhosis. 2. Further, rare mutations in CIDEB are associated with a decreased risk of nonalcoholic fatty liver disease. Evidence Rating Level: 1 (Excellent) Study Rundown: For patients with obesity and nonalcoholic fatty liver disease, the risk of progression to steatohepatitis and

Exploring medication adherence and its associated factors among hypertension outpatients attending a tertiary-level cardiovascular hospital in Tanzania

Determining self-care practice and its associated factors among podoconiosis patients in East Gojjam zone North West, Ethiopia.